← Browse by Condition
Medical Condition

gastrointestinal stromal tumors

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for gastrointestinal stromal tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — gastrointestinal stromal tumors Clinical Trials

How many clinical trials are currently recruiting for gastrointestinal stromal tumors?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for gastrointestinal stromal tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gastrointestinal stromal tumors?
gastrointestinal stromal tumors research spans Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gastrointestinal stromal tumors clinical trial?
Eligibility criteria for gastrointestinal stromal tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Top Sponsors
Fujian Medical University 1 trial
Reema A. Patel 1 trial
Asan Medical Center 1 trial
Grupo Espanol de Investigacion en Sarcomas 1 trial

Recruiting Clinical Trials

NCT05938309
Recruiting
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
Enrollment
194 pts
Location
China
Sponsor
Fujian Medical University
View Trial →
NCT05493215 Phase 2
Recruiting
Imatinib TDM in GIST
Enrollment
28 pts
Location
United States
Sponsor
Reema A. Patel
View Trial →
NCT05905887 Phase 2
Recruiting
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Enrollment
48 pts
Location
South Korea
Sponsor
Asan Medical Center
View Trial →
NCT04181970
Recruiting
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Enrollment
5,000 pts
Location
Argentina, Brazil, C...
Sponsor
Grupo Espanol de Investigacion...
View Trial →

Related Conditions

soft tissue sarcoma (1) bone sarcoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology